FLT-3: A new focus in the understanding of acute leukemia

International Journal of Biochemistry and Cell Biology

Volumn 37, Issue 6, 2005, Pages 1168-1172

  Markovic, Ana ^a,b   MacKenzie, Karen L ^a,b   Lock, Richard B ^a,b  

^a CHILDREN S CANCER INSTITUTE AUSTRALIA FOR MEDICAL RESEARCH   (Australia)

^b UNIVERSITY OF NEW SOUTH WALES   (Australia)

Author keywords

FLT 3; Leukemia; Targeted therapy

Indexed keywords

4 [6 METHOXY 7 [3 (1 PIPERIDINYL)PROPOXY] 4 QUINAZOLINYL] 1 PIPERAZINECARBOXYLIC ACID (4 ISOPROPOXYPHENYL)AMIDE; CEP 701; MIDOSTAURIN; SEMAXANIB; SUNITINIB; VASCULOTROPIN RECEPTOR 3;

ACUTE LEUKEMIA; CELL FUNCTION; CLINICAL TRIAL; GENE STRUCTURE; HEMATOPOIESIS; HEMATOPOIETIC CELL; HUMAN; MUTATION; PROGNOSIS; PROTEIN DEGRADATION; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN STRUCTURE; PROTEIN SYNTHESIS; REVIEW;

EID: 15044355643     PISSN: 13572725     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.biocel.2004.12.005     Document Type: Short Survey

References (21)

1. S.A. Armstrong, A.L. Kung, M.E. Mabon, L.B. Silverman, R.W. Stam, and M.L. Den Boer Inhibition of FLT3 in MLL: validation of a therapeutic target identified by gene expression based classification Cancer Cell 3 2003 173 183
2. W. Fiedler, H. Serve, H. Dohner, M. Schwittay, O.G. Ottmann, and A.M. O'Farrell A phase I study of SU11248 in the treatment of patients with refractory or resistant acute myeloid leukemia (AML) or not amenable to conventional therapy for the disease Blood (First Edition Paper) 2004
3. F.J. Giles, A.T. Stopeck, L.R. Silverman, J.E. Lancet, M.A. Cooper, and A.L. Hannah SU5416, a small molecule tyrosine kinase receptor inhibitor, has biologic activity in patients with refractory acute myeloid leukemia or myelodysplastic syndromes Blood 102 2003 795 801
4. D.G. Gilliland, and J.D. Griffin The roles of FLT3 in hematopoiesis and leukemia Blood 100 2002 1532 1542
5. R. Karlsson, M. Engstrom, M. Jonsson, P. Karlberg, C.J.H. Pronk, and J. Richter Phosphatidylinositol 3-kinase is essential for kit ligand-mediated survival, whereas interleukin-3 and flt3 ligand induce expression of antiapoptotic Bcl-2 family genes Journal of Leukocyte Biology 74 2003 923 931
6. L.M. Kelly, J.C. Yu, C.L. Boulton, M. Apatira, J. Li, and C.M. Sullivan CT53518, a novel selective FLT3 antagonist for the treatment of acute myelogenous leukemia (AML) Cancer Cell 1 2002 421 432
7. M. Lisovsky, Z. Estrov, X. Zhang, U. Consoli, G. Sanchez-Williams, and V. Snell Flt3 ligand stimulates proliferation and inhibits apoptosis of acute myeloid leukemia cells: Regulation of Bcl-2 and Bax Blood 88 1996 3987 3997
8. K. Mackarehtschian, J.D. Hardin, K.A. Moore, S. Boast, S.P. Goff, and I.R. Lemischka Targeted disruption of the flk2/flt3 gene leads to deficiencies in primitive hematopoietic progenitors Immunity 3 1995 147 161
9. H.J. McKenna, K.L. Stocking, R.E. Miller, K. Brasel, T. De Smedt, and E. Maraskovsky Mice lacking flt3 ligand have deficient hematopoiesis affecting hematopoietic progenitor cells, dendritic cells, and natural killer cells Blood 95 2000 3489 3497
10. S. Meshinchi, W.G. Woods, D.L. Stirewalt, D.A. Sweetser, J.D. Buckley, and T.K. Tjoa Prevalence and prognostic significance of Flt3 internal tandem duplication in pediatric acute myeloid leukemia Blood 97 2001 89 94
11. M. Mizuki, R. Fenski, H. Halfter, I. Matsumura, R. Schmidt, and C. Muller Flt3 mutations from patients with acute myeloid leukemia induce transformation of 32D cells mediated by the Ras and STAT5 pathways Blood 96 2000 3907 3914
12. O. Rosnet, and D. Birnbaum Hematopoietic receptors of class III receptor-type tyrosine kinases Critical Reviews in Oncology 4 1993 595 613
13. O. Rosnet, C. Schiff, M.J. Pebusque, S. Marchetto, C. Tonnelle, and Y. Toiron Human FLT3/FLK2 gene: cDNA cloning and expression in hematopoietic cells Blood 82 1993 1110 1119
14. B. Scheijen, H.T. Ngo, H. Kang, and J.D. Griffin FLT3 receptors with internal tandem duplications promote cell viability and proliferation by signaling through Foxo proteins Oncogene 23 2004 3338 3349
15. L.Y. Shih, C.F. Huang, J.H. Wu, P.N. Wang, T.L. Lin, and P. Dunn Heterogeneous patterns of FLT3 Asp835 mutations in relapsed de novo acute myeloid leukemia: a comparative analysis of 120 paired diagnostic and relapse bone marrow samples Clinical Cancer Research 10 2004 1326 1332
16. B.D. Smith, M. Levis, M. Beran, F. Giles, H. Kantarjian, and K. Berg Single-agent CEP-701, a novel FLT3 inhibitor, shows biologic and clinical activity in patients with relapsed or refractory acute myeloid leukemia Blood 103 2004 3669 3676
17. D.L. Stirewalt, and J.P. Radich The role of FLT3 in haematopoietic malignancies Nature Reviews Cancer 3 2003 650 665
18. T. Taketani, T. Taki, K. Sugita, Y. Furuichi, E. Ishii, and R. Hanada FLT3 mutations in the activation loop of tyrosine kinase domain are frequently found in infant ALL with MLL rearrangements and pediatric ALL with hyperdiploidy Blood 103 2004 1085 1088
19. F. Xu, T. Taki, H.W. Yang, R. Hanada, T. Hongo, and H. Ohnishi Tandem duplication of the FLT3 gene is found in acute lymphoblastic leukaemia but not in myelodysplastic syndrome or juvenile chronic myelogenous leukaemia in children British Journal of Haematology 105 1999 155 162
20. K.W. Yee, M. Schittenhelm, A.M. O'Farrell, A.R. Town, L. McGreevey, and T. Bainbridge Synergistic Effect of SU11248 with cytarabine or daunorubicin on FLT3-ITD positive leukemic cells Blood (First Edition Paper) 104 2004 4202 4209
21. S. Yokota, H. Kiyoi, M. Nakao, T. Iwai, S. Misawa, and T. Okuda Internal tandem duplication of the FLT3 gene is preferentially seen in acute myeloid leukemia and myelodysplastic syndrome among various hematological malignancies. A study on a large series of patients and cell lines Leukemia 11 1997 1605 1609